Study S002168

Clinical Proof-of-principle of the Determination of the Beta Cell Mass in Vivo by SPECT Imaging With the 111-In-labeled GLP-1 Analogue DTPA(Diethylenetriamine Pentaacetic Acid)-[K40]-Exendin 4

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01825148
Acronym: GLP-1-CPOP
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 20
Start: 2012-12
Primary completion: 2014-05
Lead sponsor: Radboud University Medical Center
Conditions: Type 1 Diabetes
Interventions: OTHER:radiolabeled Exendin
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-000619-10

Registered primary outcomes

pancreatic uptake of radiolabeled Exendin [7 days]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0027602	Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin. Brom M, Diabetologia	2014	Nonrandomized study	PMID 24488022 DOI	cites ClinicalTrials.gov:NCT01825148; cites EudraCT:2012-000619-10; registry reference DERIVED:24488022